Vivimed Labs reports huge FY26 loss, under insolvency process

Going ConcernQualified OpinionEmphasis Of MatterRevenue DeclinePat NegativeExceptional ItemResults View source PDF

VIVIMEDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.7%1-day move

₹5.24

prior close

—

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

————-1.7-1.7-2.7-1.7-0.4—————

Up moveDown movePending

AI summary

Vivimed Labs posted a standalone net loss of Rs 1,716 million for FY26 versus Rs 315 million loss in FY25, on revenue falling to Rs 310 million from Rs 503 million. NCLT initiated Corporate Insolvency Resolution Process on April 15, 2026, suspending the board. Auditor issued a qualified opinion and flagged going concern uncertainty, citing Rs 626 million unrecorded interest and unconfirmed borrowings. A CBI investigation is also pending.

Likely market impact

Company under insolvency with losses deepening; auditor raised going concern doubt, equity holders face significant risk.